UCB's Global Corporate Website

This section is intended for media and financial analysts

Search Press releases

18 Mar 2023

Bimekizumab Phase 3 Data in Hidradenitis Suppurativa Show Clinically Meaningful, Deep and Maintained Response over 48 Weeks

Read More
17 Mar 2023

Acquisition of own shares

Read More
16 Mar 2023

UCB to Present Eight Bimekizumab Abstracts at AAD 2023 with Results from Studies in Psoriasis, Psoriatic Arthritis and Hidradenitis Suppurativa

Read More
15 Mar 2023

Aitia and UCB Announce Strategic Drug Discovery Collaboration in Huntington's Disease

Read More
10 Mar 2023

Acquisition of own shares

Read More
9 Mar 2023

Cancer Research UK Signs Multi-Project Collaboration With UCB To Advance Oncology Antibody Candidates

Read More

Stay up-to-date on the latest news and information from UCB